Diagnostics News and Research

RSS

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012

GP Strategies completes acquisition of Rovsing Dynamics

Global performance improvement solutions provider GP Strategies Corporation announced that it has completed its acquisition of operating assets of Rovsing Dynamics, a provider of vibration condition monitoring hardware and software.

27 Sep 2012

Chinese innovations, resources could help create new global health products

In this post in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Christine Rousseau, a program officer at the foundation, describes the importance of diagnostics in HIV/AIDS and tuberculosis (TB) care and treatment and writes, This brings me to the tremendous role that China's entrepreneurs can play as partners in global health.

26 Sep 2012

Pervenio Lung RS from Life Technologies

Life Technologies Corporation today announced the launch of Pervenio Lung RS. First-of-its-kind, the molecular test has been documented to reliably identify early stage lung cancer patients who are at high risk for mortality following surgery. It also fulfills an unmet need for prognostic information to guide preventative treatment and improve disease management.

25 Sep 2012

Public, private sectors must engage to increase chances of success in fighting NCDs

"Some academics and non-profit organizations are skeptical of the motives of the increasing number of multinational companies who seek partnerships to address non-communicable diseases (NCDs)," Derek Yach, senior vice president of global health and agriculture policy at PepsiCo and former head of NCDs at WHO, writes in the Huffington Post's "Impact" blog.

25 Sep 2012

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.

25 Sep 2012

FIOCRUZ, DNDi and Brazil collaborate on R&D for neglected diseases

At the opening ceremony of the XVIII International Congress for Tropical Medicines and Malaria (ICTMM) and the XLVIII Congress of the Brazilian Society of Tropical Medicine in Rio de Janeiro, the Ministry of Health of Brazil signed a Cooperation and Technical Assistance Agreement with the Oswaldo Cruz Foundation (FIOCRUZ) and the Drugs for Neglected Diseases initiative (DNDi) Latin America, uniting the three actors into a strategic partnership to collaborate on research and development (R&D) for new therapies and diagnostics for neglected diseases.

25 Sep 2012

Amcom Software launches clinical alerting middleware at St. Vincent's Melbourne

Amcom Software's Australian division today announced the launch of its Amcom Messenger clinical alerting middleware at St. Vincent's Melbourne, covering the Fitzroy, Caritas Christi, and St. George campuses.

25 Sep 2012

PAM50 potentially simplifies underlying breast tumor biology

On September 23, researchers published online in the journal Nature a study of the molecular biology of breast cancer, using the intrinsic subtypes as defined by the PAM50 gene signature as an organizing framework for analyzing genomic and proteomic aberrations. This landmark study both underscores the emergence of the intrinsic subtypes as a powerful taxonomy of breast cancer in research, and PAM50's role as the gold standard for categorizing breast cancer by subtype.

From NanoString Technologies 25 Sep 2012

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

The trained eye of a dermatologist can identify many types of skin lesions, but human sight only goes so far. Now an international team of researchers has developed an advanced optics system to noninvasively map out the network of tiny blood vessels beneath the outer layer of patients' skin, potentially revealing telltale signs of disease.

24 Sep 2012

Consumer Genetics Conference to take place in Boston from Oct. 3-5

The 4th Annual Consumer Genetics Conference, taking place October 3-5 at the Seaport Hotel in Boston, will include a keynote presentation by George Church that will provide a forthright and candid assessment of new sequencing technologies, including the emergence of nanopore DNA sequencing, current trends in personal genomics, and projections on the future path of medical genomics.

24 Sep 2012

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

Isolating and concentrating cells from whole blood: an interview with Victor Ugaz

There are several reasons for this. One is because analysis involving different kinds of blood cells may require you to be able to separate red blood cells from white blood cells, or plasma from whole blood etc.

21 Sep 2012

State roundup: HCA fined for kickbacks; Minn. rural health care investigation

The Hospital Corporation of America will pay $16.5 million to settle claims that its subsidiaries had paid a diagnostics firm for referrals, violating federal anti-kickback rules, the Justice Department announced Wednesday. HCA subsidiary Parkridge Medical Center and HCA Physician Services, both provided "financial benefits" to a physician group, Diagnostic Associates of Chattanooga, for referrals to the HCA facilities.

21 Sep 2012

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.

21 Sep 2012

'Greater commitment' needed to fight NTDs

In a guest post on USAID's "IMPACT Blog," Rachel Cohen, regional executive director of DNDi North America, writes, "The United States government and its country partners should be commended for the tremendous achievements in the fight against neglected tropical diseases (NTDs) as part of the U.S. Agency for International Development (USAID) NTD Program" and the National Institutes of Health.

20 Sep 2012

NIH announces multiple awards to UCLA Center for Autism Research and Treatment

The National Institutes of Health, recognizing UCLA's preeminence in both research and clinical care for children with autism, has announced multiple awards to the university as part of the agency's Autism Centers of Excellence (ACE) research program.

20 Sep 2012

AyoxxA Biosystems closes 2.6M Euro Series A financing round

AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.

20 Sep 2012

PCAN praises U.S. House for passage of Recalcitrant Cancer Research Act

Today, the United States House of Representatives passed unanimously the Recalcitrant Cancer Research Act (H.R. 733), formerly known as the Pancreatic Cancer Research & Education Act.

20 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012